Ellen J. Beswick, PhD

Research Interests

  • Novel Immune Targets for Cancer Therapy
  • Interaction Between Tumor Cells and the Tumor Microenvironment
  • Interrelationships Between Infection, Inflammation and Cancer

Academic Information

  • Departments: Internal Medicine - Associate Professor, Pathology - Adjunct Associate Professor
  • Divisions: Gastroenterology, Microbiology and Immunology

Academic Office Information

  • 801-213-0994
  • Maxwell M. Wintrobe Research & Education Building
    26 N Medical Dr., Room: 629
    Salt Lake City, UT 84132

Email: ellen.beswick@hsc.utah.edu

Academic Bio

Ellen J. Beswick, PhD is the Associate Director of GI Research and an Associate Professor in the Division of Gastroenterology, Department of Internal Medicine, and a member of the Huntsman Cancer Institute. Her research interests include novel immune targets for gastrointestinal cancers that can be explored in translational approaches in the hopes of developing new combination therapeutics.

Primary research interests in the Beswick lab include:

1. Uncovering the unrecognized role of G-CSF in the gastrointestinal tumor microenvironment and tumor promoting immune responses

2. Examining the role of MAP kinase-activated protein kinase 2 (MK2) in chronic inflammation and tumor-promoting pathways in gastrointestinal cancers

3. Understanding how fibroblasts regulate immune responses in the colon in inflammatory bowel disease and cancer

Click here for a full bibliography.

Education History

Type School Degree
Postdoctoral Fellowship University of Texas Medical Branch
Immunology
Postdoctoral Fellow
Doctoral Training Southern Illinois University School of Medicine
Molecular Biology, Microbiology, and Biochemistry
Ph.D.
Undergraduate Florida Southern College
Biology
B.S.

Selected Publications

Journal Article

  1. Aguirre, JE, Beswick, EJ, Grim, C Tafoya, M, Palma, GC, Samedi, V, Mckee, R, Uribe, G, Villeger, R, Starkey, JM, Cong, Y, Powell, DW, and IV Pinchuk (2019). Increased matrix metalloproteinases mediate cleavage of membrane bound PD-L1 on myo(fibroblasts): role in regulation of T helper cell responses in Crohn’s Disease. Int Immunol, ePub.
  2. Berggren KL, Restrepo Cruz S, Hixon MD, Cowan AT, Keysar SB, Craig S, James J, Barry M, Ozbun MA, Jimeno A, McCance DJ, Beswick EJ, Gan GN (2019). MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma. (Epub ahead of print) Oncogene.
  3. Phinney, BB, Ray, AL, Peretti, AS, Grim, C, Pinchuk, IV, and EJ Beswick (2018). MK2 regulates macrophage chemokine activity and recruitment to promote colon tumor growth. Front Immunol.
  4. Beswick EJ, Singh, A, Grim, C, Aguirre, J, Qiu, S, Rogler, G, McKee, R, Ma, TY, Reyes, VE, Powell, DW, and IV Pinchuk CD90 stromal cell mediated PD-L1 signaling is differentially disrupted in Crohns Disease vs Ulcerative Colitis contributing to the dysregulation of T helper cell responses (2018). Expression of Programmed Death-Ligand 1 by Human Colonic CD90+ Stromal Cells Differs Between Ulcerative Colitis and Crohn's Disease and Determines Their Capacity to Suppress Th1 Cells. Front Immunol, 30(9), 1125.
  5. Ray, AL, Berggren, K, Cruz, SR, Gan, GN, and EJ Beswick (2018). Inhibition of MK2 suppresses IL-1β, IL-6, and TNF-α-dependent colorectal cancer growth. Int J Cancer, 142(8), 1702-11.
  6. Ray, AL, Castillo, EF, Morris, KT, Nofchissey, RA, Weston, LL, Samedi, VG, Hanson, JA, Pinchuk, IV, and EJ Beswick (2016). Blockade of the MK2 pathway is protective in inflammation-associated colorectal cancer development. Int J Cancer, 138(3), 770-5.
  7. Morris, KT, Castillo, EF, Weston, LL, Nofchissey, RA, Ray, AL, Hanson, JA, Samedi, Hudson, LG and EJ Beswick (2015). Anti-G-CSF treatment induces protective immunity in mouse colon cancer by promoting protective NK cell, macrophage and T cell responses. Oncotarget, 6(26), 22338-47.
  8. Beswick EJ, Saada JI, Johnson JR, Humen M, House J, Dann SM, Qiu S, Powell DW, Reyes VE, and IV Pinchuk (2014). TLR4 activation enhances the PD-L1-mediated tolerogenic capacity of colonic CD90+ stromal cells. J Immunol, 193(5), 2218-29.
  9. Morris, KT, Khan, H, Ahmad, A, Weston, LL, Nofchissey, RA, Pinchuk, IV, and EJ Beswick (2014). G-CSFR is over-expressed in human gastric and colon cancers and promotes carcinoma cell proliferation and migration. Br J Cancer, 110(5), 1211-20.

Patent

  1. Beswick EJ (2019). MK2 combined therapy to treat cancer.
  2. Beswick EJ (2019). Inhibition of Granulocyte Colony Stimulating Factor as a sole or combination treatment for solid tumors.
  3. Beswick EJ (2019). Inhibition of the Map kinase activated protein kinase 2 (MK2) as a sole or combination treatment for gastrointestinal cancers.